All Stories

Premaitha - good AGM statement: Buy

Tom Winnifrith
Thursday 6 November 2014

Premaitha Health (NIPT) has updated investors attending its AGM that it believes its lead product “remains on target to be the first regulated CE marked ‘in vitro’ diagnostic product in the rapidly growing market for non-invasive prenatal screening”.

This is with development and launch preparations on schedule, with the test having performed well in verification studies and the company having received positive feedback on its quality systems and regulatory strategy. It is noted that “recruitment of commercialisation and technical support teams is ongoing” and that the company has presented the test at a number of conferences – with positive private and public body interest in the product from the UK, Europe, Asia and Australasia.

on ShareProphets | Comments

Filed under:

About Tom Winnifrith
Bio
Tom Winnifrith is the editor of TomWinnifrith.com. When he is not harvesting olives in Greece, he is (planning to) raise goats in Wales.
Twitter
@TomWinnifrith
Email
[email protected]
Recently Featured on ShareProphets
Sign up for my weekly newsletter








Required Reading

Recent Comments


I also read